John C. Byrd, MD

University of Cincinnati College of Medicine

N/A

Poster(s):

• 1004 - The PKCβ inhibitor MS-553 displays preclinical efficacy in BTK inhibitor resistant Chronic Lymphocytic Leukemia

• 1120 - Single-cell RNA-seq analysis reveals distinct tumor and immunosuppressive T cell phenotypes in CLL patients treated with ibrutinib.

• 1123 - Anti-CD19 Chimeric Antigen Receptor T-cell therapy for Richter’s Transformation: A Multicenter Retrospective Study

• 3003 - COVALENT-101: Phase I Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL (NCT05153330)